BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/3/2026 6:28:09 AM | Browse: 2 | Download: 14
 |
Received |
|
2025-10-14 09:10 |
|
Peer-Review Started |
|
2025-10-14 09:10 |
|
First Decision by Editorial Office Director |
|
2025-10-24 06:33 |
|
Return for Revision |
|
2025-10-24 06:33 |
|
Revised |
|
2025-11-21 06:36 |
|
Publication Fee Transferred |
|
2025-11-24 11:53 |
|
Second Decision by Editor |
|
2025-12-18 02:40 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-12-18 07:55 |
|
Articles in Press |
|
2025-12-18 07:55 |
|
Edit the Manuscript by Language Editor |
|
2025-12-24 04:25 |
|
Typeset the Manuscript |
|
2026-01-27 00:35 |
|
Publish the Manuscript Online |
|
2026-02-03 06:28 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
Clinical efficacy of Fuzheng Jiedu Xiaoyong granules in advanced colorectal cancer (spleen deficiency and stasis toxin syndrome)
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Hai-Yun Qin, Zheng Li, Pei-Wei Cong, Dan Mi, Feng-Zhen Li, Xin Hu and Guo-Xin Li |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Guo-Xin Li, Chief Physician, PhD, Professor, Guoyi Hall, The Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, No. 60, Huanghe North Street, Huanggu District, Shenyang City, Liaoning Province, China, Shenyang 110034, Liaoning Province, China. syyljdlgx024@126.com |
| Key Words |
Advanced colorectal cancer; Fuzheng Jiedu Xiaoyong granules; First-line therapy; Randomized controlled trial; Immune function |
| Core Tip |
The combination of Fuzheng Jiedu Xiaoyong granules (FZJDXYG) with first-line therapy for advanced colorectal cancer (CRC) demonstrates significant clinical efficacy with minimal adverse effects. It has effectively modulated immune dysfunction and improved patients’ quality of life. A parallel, randomized, controlled trial confirmed the significant efficacy and high safety of FZJDXYG in treating advanced CRC patients. Moreover, FZJDXYG significantly increased the CD4+ T cell ratio, reduced the CD8+ T cell ratio, and elevated the CD4+/CD8+ ratio in patients, with significant differences both before and after treatment, as well as between the treatment and control group. |
| Publish Date |
2026-02-03 06:28 |
| Citation |
Qin HY, Li Z, Cong PW, Mi D, Li FZ, Hu X, Li GX. Clinical efficacy of Fuzheng Jiedu Xiaoyong granules in advanced colorectal cancer (spleen deficiency and stasis toxin syndrome). World J Gastrointest Oncol 2026; 18(2): 113922 |
| URL |
https://www.wjgnet.com/1948-5204/full/v18/i2/113922.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v18.i2.113922 |
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
